A clinical research study testing olaparib, in Homologous recombination (HR) deficient metastatic breast and relapsed ovarian cancer in patients who do not have hereditary mutations in Breast Cancer susceptibility gene 1 and gene 2 (BRCA1 and BRCA2)

 

Trial Summary:

The aim of this trial is to determine if tumours with somatic inactivating mutations of BRCA1 or BRCA2, germline or somatic inactivating mutations in other genes involved in repairing homologous recombination defects (e.g. PALB2, CHEK2, ATM, RAD51), or somatic BRCA1 gene silencing by promoter methylation are similarly susceptible to PARP inhibition as tumours with germline inactivating mutations of BRAC1 or BRAC2.

Supported By:

Cancer Australia, Astra Zeneca, GCCTI, ANZGOG, BCT

Eligibility:

Men or women with confirmed evidence of metastatic triple negative breast cancer (TNBC) or women with confirmed evidence of relapsed high grade serous ovarian cancer (including fallopian tube cancer or primary peritoneal cancer) or high grade endometrioid ovarian cancer (HGSOC)

Registration ID:

ACTRN12617000855325

Participation:

Australia

Australian Lead Group:

NHMRC CTC

Status:

Open

Activation Date:

13.10.2017

Chairs:

Katrin Sjoquist (NHMRC CTC, St George Hospital)

Contact:

EMBRACE@ctc.usyd.edu.au